Sub Heading

Clinical Trials Details

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

IRB Protocol Number
URCC- 21038 Direct

Clinical Trial Categories

  • Solid Tumors
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Black or white, men or women, ages 18 and older, scheduled to receive cancer treatment with Immunotherapy

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.